LAVA Therapeutics Analyst Ratings
LAVA Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/17/2023 | 305.41% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 08/23/2023 | 305.41% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
| 08/23/2023 | 305.41% | HC Wainwright & Co. | $9 → $6 | Maintains | Buy |
| 06/15/2023 | 305.41% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
| 06/12/2023 | 508.11% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 06/09/2023 | 305.41% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
| 04/13/2023 | 508.11% | HC Wainwright & Co. | → $9 | Reiterates | → Buy |
| 02/17/2023 | 508.11% | HC Wainwright & Co. | → $9 | Reiterates | → Buy |
| 10/25/2022 | 508.11% | HC Wainwright & Co. | → $9 | Initiates Coverage On | → Buy |
| 09/27/2022 | 1791.89% | SVB Leerink | $25 → $28 | Maintains | Outperform |
| 09/15/2022 | 305.41% | JMP Securities | → $6 | Initiates Coverage On | → Market Outperform |
| 05/18/2022 | 1589.19% | SVB Leerink | $23 → $25 | Maintains | Outperform |
| 11/16/2021 | 1251.35% | SVB Leerink | $24 → $20 | Maintains | Outperform |
| 08/17/2021 | 1521.62% | SVB Leerink | $26 → $24 | Maintains | Outperform |
| 04/19/2021 | 1454.05% | Jefferies | → $23 | Initiates Coverage On | → Buy |
| 04/19/2021 | 1386.49% | JP Morgan | → $22 | Initiates Coverage On | → Overweight |
| 04/19/2021 | 1656.76% | SVB Leerink | → $26 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/17/2023 | 305.41% | HC Wainwright & Co. | → 6 美元 | 重申 | 購買 → 購買 |
| 08/23/2023 | 305.41% | JMP 證券 | → 6 美元 | 重申 | 市場跑贏大盤 → 市場跑贏大盤 |
| 08/23/2023 | 305.41% | HC Wainwright & Co. | 9 美元 → 6 美元 | 維護 | 買 |
| 06/15/2023 | 305.41% | JMP 證券 | → 6 美元 | 重申 | 市場跑贏大盤 → 市場跑贏大盤 |
| 06/12/2023 | 508.11% | HC Wainwright & Co. | → 9 美元 | 重申 | 購買 → 購買 |
| 06/09/2023 | 305.41% | JMP 證券 | → 6 美元 | 重申 | 市場跑贏大盤 → 市場跑贏大盤 |
| 04/13/2023 | 508.11% | HC Wainwright & Co. | → 9 美元 | 重申 | → 購買 |
| 02/17/2023 | 508.11% | HC Wainwright & Co. | → 9 美元 | 重申 | → 購買 |
| 10/25/2022 | 508.11% | HC Wainwright & Co. | → 9 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 09/27/2022 | 1791.89% | SVB Leerink | 25 美元 → 28 美元 | 維護 | 跑贏大盤 |
| 2022 年 9 月 15 日 | 305.41% | JMP 證券 | → 6 美元 | 啓動覆蓋範圍開啓 | → 市場跑贏大盤 |
| 05/18/2022 | 1589.19% | SVB Leerink | 23 美元 → 25 美元 | 維護 | 跑贏大盤 |
| 11/16/2021 | 1251.35% | SVB Leerink | 24 美元 → 20 美元 | 維護 | 跑贏大盤 |
| 2021 年 8 月 17 日 | 1521.62% | SVB Leerink | 26 美元 → 24 美元 | 維護 | 跑贏大盤 |
| 2021 年 4 月 19 日 | 1454.05% | 傑富瑞集團 | → 23 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 4 月 19 日 | 1386.49% | 摩根大通 | → 22 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 2021 年 4 月 19 日 | 1656.76% | SVB Leerink | → 26 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for LAVA Therapeutics (LVTX)?
LAVA Therapeutics（LVTX）的目標價格是多少？
The latest price target for LAVA Therapeutics (NASDAQ: LVTX) was reported by HC Wainwright & Co. on November 17, 2023. The analyst firm set a price target for $6.00 expecting LVTX to rise to within 12 months (a possible 305.41% upside). 8 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月17日公佈了LAVA Therapeutics（納斯達克股票代碼：LVTX）的最新目標股價。該分析公司將目標股價定爲6.00美元，預計LVTX將在12個月內升至12個月內（可能上漲305.41％）。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for LAVA Therapeutics (LVTX)?
LAVA Therapeutics（LVTX）的最新分析師評級是多少？
The latest analyst rating for LAVA Therapeutics (NASDAQ: LVTX) was provided by HC Wainwright & Co., and LAVA Therapeutics reiterated their buy rating.
HC Wainwright & Co. 提供了LAVA Therapeutics（納斯達克股票代碼：LVTX）的最新分析師評級，LAVA Therapeutics重申了其買入評級。
When is the next analyst rating going to be posted or updated for LAVA Therapeutics (LVTX)?
LAVA Therapeutics（LVTX）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of LAVA Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for LAVA Therapeutics was filed on November 17, 2023 so you should expect the next rating to be made available sometime around November 17, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與LAVA Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。LAVA Therapeutics的最新評級是在2023年11月17日公佈的，因此您應該預計下一個評級將在2024年11月17日左右公佈。
Is the Analyst Rating LAVA Therapeutics (LVTX) correct?
分析師對LAVA Therapeutics（LVTX）的評級正確嗎？
While ratings are subjective and will change, the latest LAVA Therapeutics (LVTX) rating was a reiterated with a price target of $0.00 to $6.00. The current price LAVA Therapeutics (LVTX) is trading at is $1.48, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的LAVA Therapeutics（LVTX）評級，目標股價爲0.00美元至6.00美元。LAVA Therapeutics（LVTX）目前的交易價格爲1.48美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。